of patients at previously known sites; in three cases new metastatic sites were observed. Patients with primary localized tumors who had been treated with HDC Patients with primary metastatic or recurrent rhabdomyosarcoma (RMS) have a very poor prognosis. Since because of relapse did slightly better (four of nine alive with NED) than patients with primary metastatic dishigh-dose chemotherapy (HDC) ؎ TBI was thought to improve survival, many centers performed this therease (five of 27 alive with NED). HDC is still of uncertain value in the therapy of poor-risk rhabdomyosarapy using different types of hematopoietic rescue (auto BM or PBSC, allo BM). This is a retrospective, multicoma and should be performed only as part of controlled clinical trials. center analysis of the results of treatment in 36 patients with primary metastatic or relapsed RMS who were Keywords: rhabdomyosarcoma; high-dose therapy; soft tissue sarcoma given HDC ؎ TBI and hematopoietic rescue between 1986 and 1994. The median age was 6 years (Ͻ1-22 years). Primary therapy was given according to either one of the Cooperative German Soft Tissue Sarcoma
) in 26 patients, 10 of whom received
It is interesting to note that the results of treatment have additional FTBI. Seven patients were treated with melchanged little over the last 20 years. The chance of being phalan alone or in combination with carboplatin. Two cured after relapse of primary localized RMS depends on patients received cyclophosphamide/busulphan with the intensity of the primary chemotherapy, on the histologi-TLI (total lymphoid irradiation) and one cyclophoscal subtype and whether radiotherapy was given. In the phamide with FTBI. Thirty-one patients were given German Cooperative Soft Tissue Sarcoma Studies CWS-81 autologous BM or PBSC as hematopoietic rescue and and CWS-86 only patients with embryonal rhabdomyosarfive allogeneic bone marrow from HLA-identical sibcoma who relapsed locally and in whom local irradiation lings. Fourteen patients received GM-CSF or G-CSF was still feasible had a slightly better chance of survival after hematopoietic stem cell transfusion (HSCT). Ten with a survival rate at 3 years of 62% (data not published). patients received adjuvant IL-2. There was one toxic
For the remaining patients the EFS rate at 2 years did not HDC-related death. Nine patients are alive and free of exceed 20%. 7 Since RMS is a chemosensitive tumor a disease with a median observation time of 57 months further escalation of dose intensity seemed to be the best (32-108 and was shown to be effective in patients with metastatic Ewing's sarcoma. 13 There are no data about the effectiveness of single agents such as carboplatin and VP16 in rhabdomyosarcoma patients. There is, however, evidence that VP16 combined with car- rhabdomyosarcoma in xenograft models and in vivo. 18 However, there is currently no evidence that high-dose melphalan alone improves the prognosis of children with metastatic RMS.
11 Many centers cooperating in the alive with NED). Of the four patients who are alive after receiving HDC after relapse, three had lymph nodes recurGerman/Austrian Pediatric Bone Marrow Transplantation Group have therefore adapted (after 1990) the MEC schema rence and one distant metastases. Similarly, those with embryonal RMS had a better chance of disease-free suras HDC in patients with poor prognosis rhabdomyosarcoma. vival than patients with alveolar RMS, but the difference was not significant (four of 13 vs four of 22). There was Nine of 36 patients analyzed in this study are alive with NED with a median follow-up of 57 months after diagnosis. no trend for a better survival in patients treated after HDC with IL-2. Similarly, there was no difference in prognosis There was a trend for better survival in patients who were treated with HDC because of relapse of localized RMS in between patients who received FTBI vs no FTBI. None of the five patients who received allogeneic BM are alive. The comparison to patients with primary metastatic disease. However, the treatment results are no better when commedian interval between the last event that led to eligibility for HDC and the HDC itself was similar for the survivors pared to patients with metastatic or relapsed RMS registered in the German Soft Tissue Sarcoma Studies who were as compared with the entire group, ie 43 weeks (21-110) vs 44 (21-110). Relapse after HDC occurred early with a not given HDC. 5, 6 There are many questions concerning dose escalation and median interval of 4 months (1-17). Interestingly, most relapses (23) were at previously known sites with only three its relevance for cure. It has been shown in the case of acute myelogenous leukemia that no consistent gain in survival relapsing in new metastatic sites. The estimated EFS rate at 2 years after HDC is 36 Ϯ 7%, at 2 years after diagnosis although some improvement in response rate was seen with a dose of daunorubicin greater than 30 mg/m 2 . 19 No one it is 55 Ϯ 8%.
knows what is more important for primary metastatic RMS: short high-dose intensive therapy or less intensive therapy over a longer duration. Perhaps these two factors should be considered separately depending on the phase of therapy.
Discussion
In the first phase, until a complete remission is achieved, defined as no clinical signs of disease, more intensive therDespite the major improvement in prognosis for patients with primary localized rhabdomyosarcoma during the last apy is probably warranted. However, by what means should ongoing microscopic disease be eradicated? Intensive short 20 years, no significant progress has been made in the treatment of patients with primary metastatic or relapsed consolidation or low dose but longer therapy? This question has not been answered for poor prognosis RMS. Based on disease. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Rhabdomyosarcoma is a chemosensitive tumor and the role of chemotherapy, both adjuvant and the CWS studies treatment results, one can see that the dose-response relationship does not always correlate with preoperative, is well established. The intensification of chemotherapy by escalating the dose and combining more better survival. In the first German Soft Tissue Sarcoma Study CWS-81, relative intensive first-line chemotherapy drugs has been shown to improve results, especially in locally advanced, primary non-resectable rhabdomyosarwith cyclophosphamide, doxorubicin, dactinomycin and vincristine was recommended for all patients. The treatment coma. 1, 3, 16 The dose-response relationship which has been seen in many solid tumors was the theoretical basis for results were very good 3 compared to other published series. 1, 2, 4, 16 In the CWS-86 Study there was an intensification dose escalation beyond the ability of the bone marrow to reconstitute spontaneously within an acceptable period.
of of allogeneic BMT may be used as a therapeutic tool in
